Publications by authors named "R Firestone"
MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical trial included 17 patients and determined that MCARH109 is safe at a maximum tolerated dose of 150 × 10 CAR T cells. In this updated analysis, no new serious adverse events were reported at a median follow-up of 37 months.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore the link between dietary fiber intake, body fat percentage, and metabolic syndrome in Pacific and New Zealand European women.
- It involved 287 women and utilized methods such as DXA for body fat measurement and the NCI method for dietary intake assessment, revealing variations in fiber sources between the two groups.
- Results showed that lower dietary fiber intake correlated with higher body fat and increased risk of metabolic syndrome, with Pacific women consuming significantly less fiber than their New Zealand European counterparts.
Article Synopsis
- * Researchers analyzed the MMRF CoMMpass dataset and found that WEE1 expression levels can effectively distinguish between high-risk and low-risk patients, showing a significant difference in progression-free survival (PFS).
- * The findings suggest that WEE1 expression is an independent prognostic factor for MM and may lead to new therapeutic strategies by exploring the causes of abnormal WEE1 expression.
Article Synopsis
- The study aimed to investigate the prevalence of squeezable food pouches among infants and young children, and their potential effects on energy intake and body mass index (BMI).
- Researchers surveyed 933 children in New Zealand, and found that while pouch usage decreased as children grew older, the effect on their energy intake varied by age.
- Notably, preschool children who frequently used pouches consumed less energy compared to non-users, while no significant differences in BMI were observed related to pouch use, suggesting concerns about pouches may be overstated.
B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how the identification of such mechanisms before therapy initiation could refine clinical decision-making remains undefined. We analyzed outcomes for 72 RRMM patients treated with teclistamab, a CD3 × BCMA bispecific antibody, 42% (30/72) of whom had prior BCMA-directed therapy exposure.
View Article and Find Full Text PDF